{"entity":{"id":"idea-fund-payer-funded-pragmatic-trials","kind":"idea","name":"Payers fund trials of cheaper, shorter or lower-dose versions of expensive treatments","aka":[],"tldr":"Health insurers and national health systems have every reason to find out whether half the dose or half the duration of a costly drug works as well. They would fund those trials directly and keep the savings.","summary":"Payers commission pragmatic randomised trials of dose reduction, shorter duration, extended dosing intervals, stopping rules and cheaper alternatives for high-cost oncology drugs, embedded in routine care with registry endpoints. No manufacturer will run these; academic groups lack money. Precedents include the UK's REFINE-Lung (reduced-frequency pembrolizumab), the Netherlands' payer-supported trials of lower-dose abiraterone and dose-reduced ibrutinib, and the Dutch SONIA trial on CDK4/6 sequencing, whose savings dwarfed its cost. A standing payer trials fund with a savings-reinvestment rule would make this systematic.","asOf":"2026-09-08","links":[{"label":"FDA Project Optimus","url":"https://www.fda.gov/about-fda/oncology-center-excellence/project-optimus"}],"tags":[],"related":["idea-fund-implementation-quota","idea-fund-duration-trial-exclusivity","idea-fund-older-patients-trial-fund"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab","palbociclib","ribociclib"],"companies":[],"institutions":["nki"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-incentive-misalignment","b-dose-optimisation","b-drug-pricing"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"A payer trials fund of $50 million a year yields treatment-modification results whose first-year savings exceed the fund's total cost, without loss of efficacy in non-inferiority designs, for at least two of the first five trials.","rationale":"SONIA showed that deferring CDK4/6 inhibitors saved months of toxicity and large costs with no survival difference; dose-optimisation trials of abiraterone with food and of ibrutinib have shown equivalence at a fraction of the dose. Payer-funded research is standard in some countries (ZonMw in the Netherlands, NIHR HTA in the UK) but rare in oncology elsewhere.","test":"Establish the fund in one system, run five pragmatic trials with pre-specified savings estimates, and audit realised savings versus fund cost after four years.","maturity":"early-clinical","actor":"payer","cost":"medium","horizonYears":4},"route":"/ideas/idea-fund-payer-funded-pragmatic-trials/","neighbours":{"idea":[{"id":"idea-fund-implementation-quota","kind":"idea","name":"A fixed share of trial-group funding for getting proven care to patients","route":"/ideas/idea-fund-implementation-quota/"},{"id":"idea-fund-older-patients-trial-fund","kind":"idea","name":"A trials fund reserved for older and multimorbid patients","route":"/ideas/idea-fund-older-patients-trial-fund/"},{"id":"idea-fund-duration-trial-exclusivity","kind":"idea","name":"Extra exclusivity for sponsors who run treatment-duration and de-escalation trials","route":"/ideas/idea-fund-duration-trial-exclusivity/"},{"id":"idea-fund-course-based-radiotherapy-payment","kind":"idea","name":"Pay per course of radiotherapy, not per session, so short courses are not penalised","route":"/ideas/idea-fund-course-based-radiotherapy-payment/"},{"id":"idea-fund-omission-deescalation-trials","kind":"idea","name":"Payer-funded trials that omit surgery or radiotherapy in low-risk patients","route":"/ideas/idea-fund-omission-deescalation-trials/"}],"drug":[{"id":"palbociclib","kind":"drug","name":"Palbociclib","route":"/drugs/palbociclib/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"ribociclib","kind":"drug","name":"Ribociclib","route":"/drugs/ribociclib/"}],"institution":[{"id":"nki","kind":"institution","name":"Netherlands Cancer Institute (NKI-AvL)","route":"/institutions/nki/"}],"bottleneck":[{"id":"b-incentive-misalignment","kind":"bottleneck","name":"Incentives reward me-too drugs and marginal gains","route":"/bottlenecks/b-incentive-misalignment/"},{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/"},{"id":"b-dose-optimisation","kind":"bottleneck","name":"Wrong doses","route":"/bottlenecks/b-dose-optimisation/"}]}}